Pratap Khedkar co-wrote this blog post with Arun Shastri.
At The Wall Street Journal Health Forum, held in Washington D.C. on April 30, Novartis Chief Executive Vas Narasimhan called artificial intelligence “another tool in the toolbox.” This viewpoint diverges from recent notions that AI is a critical capability that’s going to change the way that pharma companies do business. In fact, industry experts have hoped that the dwindling return on investments for R&D (the current 3% ROI is predicted to hit 0% by 2020) could be reversed by employing AI-based technologies in drug discovery. There are more than 100 AI startups in this field that have received generous investments from venture capital. Yet, IBM has discontinued sales of its Watson AI system for drug discovery.
D. Sahay co-wrote this article with Arun Shastri
This post is the second in a two-part series.
Presenting at the 2018 PMSA Annual Conference provided us with the opportunity to think through some common myths about AI. Before our presentation, we spoke with colleagues and clients, and settled on the following five persistent myths:
Dharmendra Sahay co-wrote this blog post with Arun Shastri.
This post is the first in a two-part series.
In a few days, we’ll be presenting our thoughts on how to create impact with artificial intelligence at the 2018 PMSA Annual Conference. We’ll talk about how AI is being used in life sciences and how AI could be used, and we’ll bust some myths. We’ll also share detailed advice on how to start or expand an AI capability at your organization, which includes these five critical steps: